Table 1.
Adverse Events by CTCAE Version 4 Classification in 17 Patients Treated with Vemurafenib
| Adverse event | All grades N (%) | Grade 1 N (%) | Grade 2 N (%) | Grade 3 N (%) | Grade 4 N (%) |
|---|---|---|---|---|---|
| Overall (at least one AE) | 17 (100) | 15 (88) | 16 (94) | 7 (41) | 1 (6) |
| Fatigue | 12 (71) | 9 (53) | 2 (12) | 1 (6) | - |
| Weight loss | 12 (71) | 8 (47) | 4 (24) | - | - |
| Anorexia | 11 (65) | 5 (29) | 6 (35) | - | - |
| Arthralgias | 10 (59) | 5 (29) | 5 (29) | - | - |
| Hair loss | 10 (59) | 9 (53) | 1 (6) | - | - |
| Rash | 10 (59) | 5 (29) | 5 (29) | - | - |
| Hand-foot syndrome | 9 (53) | 5 (29) | 3 (18) | 1 (6) | - |
| Calluses | 8 (47) | 8 (47) | - | - | - |
| Diarrhea | 8 (47) | 6 (35) | 2 (12) | - | - |
| Fever | 7 (41) | 7 (41) | - | - | - |
| Dry mouth | 6 (35) | 4 (24) | 2 (12) | - | - |
| Nausea | 6 (35) | 5 (29) | 1 (6) | - | - |
| Verrucous keratosis | 6 (35) | - | 6 (35) | - | - |
| Photosensitivity | 4 (24) | 1 (6) | 2 (12) | 1 (6) | - |
| Mucositis | 3 (18) | 2 (12) | 1 (6) | - | - |
| Weakness | 3 (18) | 2 (12) | 1 (6) | - | - |
| Squamous cell skin carcinoma | 3 (18) | - | - | 3 (18) | - |
| Blurry vision | 2 (12) | 2 (12) | - | - | - |
| Dysgeusia | 2 (12) | - | 2 (12) | - | - |
| Hoarseness | 2 (12) | 2 (12) | - | - | - |
| HTN | 2 (12) | 1 (6) | 1 (6) | - | - |
| Vomiting | 2 (12) | 2 (12) | - | - | - |
| Constipation | 1 (6) | 1 (6) | - | - | - |
| Headache | 1 (6) | 1 (6) | - | - | - |
| Nail changes | 1 (6) | 1 (6) | - | - | - |
| Palmar warts | 1 (6) | 1 (6) | - | - | - |
| QT prolongation | 1 (6) | 1 (6) | - | - | - |
| Melanocytic nevi | 1 (6) | - | 1 (6) | - | - |
| Atrial fibrillation | 1 (6) | - | 1 (6) | - | - |
| Gum lesion | 1 (6) | - | 1 (6) | - | - |
| Uveitis | 1 (6) | - | - | 1 (6) | - |
| Elevated serum lipase | 1 (6) | - | - | - | 1 (6) |
Abbreviations: HTN, hypertension; -, not observed.